Lineage Cell Therapeutics earnings were -$18.6M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest LCTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$3.3M, up 7.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LCTX reported annual earnings of -$18.6M, with -13.4% growth. The next LCTX earnings date is May 7, 2025.
Lineage Cell Therapeutics Earnings Reports & History FAQ
What were Lineage Cell Therapeutics's earnings last quarter?
On LCTX's earnings call on Invalid Date, Lineage Cell Therapeutics (NYSEMKT: LCTX) reported Q4 2024 earnings per share (EPS) of -$0.01, up 50% year over year. Total LCTX earnings for the quarter were -$3.27 million. In the same quarter last year, Lineage Cell Therapeutics's earnings per share (EPS) was -$0.02.
When does Lineage Cell Therapeutics report earnings?
The next LCTX earnings call is Invalid Date. Add LCTX to your watchlist to be reminded of Lineage Cell Therapeutics's next earnings date.
What was LCTX's earnings growth in the past year?
As of Lineage Cell Therapeutics's earnings date in Invalid Date, Lineage Cell Therapeutics's earnings has grown year over year. LCTX earnings in the past year totalled -$18.61 million.
Is Lineage Cell Therapeutics profitable or losing money?
As of the last Lineage Cell Therapeutics earnings report, Lineage Cell Therapeutics is currently losing money. Lineage Cell Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$18.61 million, a 13.39% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.